WO2009137270A3 - Azetidine derivatives - Google Patents

Azetidine derivatives Download PDF

Info

Publication number
WO2009137270A3
WO2009137270A3 PCT/US2009/041343 US2009041343W WO2009137270A3 WO 2009137270 A3 WO2009137270 A3 WO 2009137270A3 US 2009041343 W US2009041343 W US 2009041343W WO 2009137270 A3 WO2009137270 A3 WO 2009137270A3
Authority
WO
WIPO (PCT)
Prior art keywords
azetidine derivatives
disorders
mch
metabolic
bind
Prior art date
Application number
PCT/US2009/041343
Other languages
French (fr)
Other versions
WO2009137270A2 (en
Inventor
Yu Jiang
Gil Ma
Kai Lu
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of WO2009137270A2 publication Critical patent/WO2009137270A2/en
Publication of WO2009137270A3 publication Critical patent/WO2009137270A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to azetidine derivatives which bind to the MCH l receptor. In separate aspects, the subject invention is directed to uses of said compounds in the preparation of a pharmaceutical composition for the treatment of metabolic and CNS related disorders and to methods of treating said disorders comprising administering a therapeutically effective amount of a compound of the invention.
PCT/US2009/041343 2008-05-09 2009-04-22 Azetidine derivatives WO2009137270A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5183908P 2008-05-09 2008-05-09
US61/051,839 2008-05-09

Publications (2)

Publication Number Publication Date
WO2009137270A2 WO2009137270A2 (en) 2009-11-12
WO2009137270A3 true WO2009137270A3 (en) 2009-12-30

Family

ID=41265293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/041343 WO2009137270A2 (en) 2008-05-09 2009-04-22 Azetidine derivatives

Country Status (1)

Country Link
WO (1) WO2009137270A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6129850B2 (en) * 2012-01-12 2017-05-17 武田薬品工業株式会社 Benzimidazole derivatives as MCH receptor antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010446A2 (en) * 2004-07-27 2006-02-02 7Tm Pharma A/S Medicinal use of receptor ligands
WO2006015279A1 (en) * 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
WO2006044174A2 (en) * 2004-10-13 2006-04-27 Neurogen Corporation Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010446A2 (en) * 2004-07-27 2006-02-02 7Tm Pharma A/S Medicinal use of receptor ligands
WO2006015279A1 (en) * 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
WO2006044174A2 (en) * 2004-10-13 2006-04-27 Neurogen Corporation Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor

Also Published As

Publication number Publication date
WO2009137270A2 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
WO2009106980A3 (en) Indazole derivatives
MX2007009649A (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer.
PH12013501341A1 (en) Morphinan compounds
WO2010017545A3 (en) Triazole compounds that modulate hsp90 activity
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
WO2009002808A3 (en) Quinazolinone compounds and methods of use thereof
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
WO2009036996A3 (en) Small molecule bradykinin b1 receptor antagonists
MX2011006006A (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders.
WO2009026446A3 (en) Hdac inhibitors
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
EA201171088A1 (en) TREATMENT OF DISKINESIA IN DIFFERENT DISORDERS
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof
MX2010009462A (en) Indazole derivatives.
WO2010036567A3 (en) Harmine compounds for promoting bone growth
WO2010019701A3 (en) Diaryl urea derivatives
MX2010008690A (en) Dual pharmacophores-pde4-muscarinic antagonistics.
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
ATE538105T1 (en) SUBSTITUTED TETRAZOLE COMPOUNDS AND THEIR USE
WO2010002835A3 (en) Vinpocetine and eburnamonine derivatives for promoting bone growth
WO2010039920A3 (en) Boldine compounds for promoting bone growth
WO2009019693A3 (en) Analgesic effect of jasmonate derivatives
WO2010012817A3 (en) 5ht7 receptor ligands and compositions comprising the same
WO2009088992A3 (en) Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09743257

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09743257

Country of ref document: EP

Kind code of ref document: A2